,163 A clinical phase 1 trial targeting the CCL2/CCR2 signaling axis showed positive results, with an objective tumor response occurring in 49% and local tumor control in 97% of patients treated with the CCR2 antagonist PF-04136309 in combination with FOLFIRINOX chemotherapy.164. The gene discussed is CCR2; the disease is neoplasm.